An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials. The DSMB Recommended the Phase 3 Trials of Simufilam Continue as Planned, Without Modification AUSTIN, Texas, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced a positive... Read More

New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease. Results corroborate prior research from other academic researchers. These data once again confirm the biological activity of simufilam. AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the publication... Read More

AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present at the following investor conferences. Event: Morgan Stanley - 21 st Annual Global Healthcare Conference Format: Fireside chat with Remi Barbier, President & CEO Date: Monday, September 11, 2023 Where:... Read More

Results of a randomized, controlled trial of oral simufilam in Alzheimer’s disease announced July 2023. Over 1,587 patients now enrolled in Phase 3 studies of simufilam in Alzheimer’s disease, an increase of over 340 patients in the last three months. Completion of patient enrollment for Phase 3 program still expected Q4 2023. $168.4 Million in Cash and Cash Equivalents at June 30, 2023. AUSTIN, Texas, Aug. 03, 2023 (GLOBE... Read More

Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease. Drug Effects Favored Mild Alzheimer’s Disease. In Mild Alzheimer’s, Simufilam Improved Cognition Scores Over 6 Months. In Mild Alzheimer’s, Simufilam Stabilized Cognition Scores Over 18 Months. Oral... Read More

Overactive mTOR Plays a Key Role in Aging and Alzheimer’s Disease. Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect. Research is Published in Frontiers in Aging , a Peer-reviewed Journal. AUSTIN, Texas, June 27, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the publication of a new paper in Frontiers in Aging , a peer-reviewed... Read More

Publication Reviews Certain Receptor-Protein Interactions. Provides Overview of Basic Science Supporting Simufilam. Published in Drug Development Research , a Peer-Reviewed Journal. AUSTIN, Texas, June 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced a new science publication in Drug Development Research , a... Read More

AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that its management has been invited to present at the Jefferies Global Healthcare Conference in New York City. When : Thursday, June 8th at 4:30 pm Eastern time Live Webcast :... Read More

The Cognition Maintenance Study (CMS) is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease. Primary Outcome Measures Are Safety and Change in Cognition Scores. Top-line Clinical Results of the CMS Are Expected in Q3 2023. AUSTIN, Texas, May 11, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the completion... Read More

New in vitro data from Europe show that simufilam can reverse altered filamin A protein (FLNA) in pituitary tumor cells, leading to improved cell signaling Data suggest FLNA is a central factor influencing pituitary tumor cell behavior Data to be presented at the European Society of Endocrinology, May 13-16 th AUSTIN, Texas, May 08, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage... Read More

O ver 1,244 Alzheimer’s patients now enrolled in Phase 3 studies of simufilam. Completion of patient enrollment for Phase 3 program still expected Q4 2023. $187.5 Million Cash and Cash Equivalents at March 31, 2023. AUSTIN, Texas, May 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first... Read More

AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier, President & Chief Executive Officer, has been invited to present at the 2023 H.C. Wainwright BioConnect Investor Conference in New York. In addition, management will be available for one-on-one meetings with institutional investors... Read More

In Q2 2023, We Expect to Complete Patient Dosing for our Cognition Maintenance Study in Alzheimer’s disease. In Q3 2023, We Expect to Announce Results of our Cognition Maintenance Study. In Q4 2023, We Expect to Complete Patient Enrollment for our Phase 3 Studies of Simufilam in Alzheimer’s disease. Mid-year 2023, We Expect an Independent Third Party to Present Evidential Data for The Biological Activity of Simufilam Outside... Read More

953 Alzheimer’s Patients Are Now Enrolled Across Phase 3 Studies Both Phase 3 Studies Have Passed the Halfway Mark for Enrollment Goal Is to Complete Enrollment for Both Phase 3 Studies by Year-End 2023 AUSTIN, Texas, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced an update on patient enrollment for its on-going Phase 3 clinical studies of... Read More

ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets. 47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 points. An additional 23% of patients declined less than 5 points on ADAS-Cog over 1 year, and this... Read More

AUSTIN, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following a brief journey with cancer, only recently discovered. “We mourn profoundly the passing of a cherished colleague and friend,” said Remi Barbier, President and CEO. “For over 20 years, he generously gave his talents, expertise and... Read More

Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately Year-End 2022, Pending Completion of Study Report by Outside Biostatisticians. AUSTIN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the... Read More

AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of its common stock, at a purchase price per share of $30, for gross proceeds of approximately $50 million. H.C. Wainwright &... Read More

AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has entered into a definitive agreement with several healthcare-focused and other institutional investors for the purchase of 1,666,667 shares of its common stock, at a purchase price of $30 per share, for... Read More

$174.7 Million Cash and Cash Equivalents at September 30, 2022 Over 650 Patients Now Enrolled in Phase 3 Program New Clinical Data for Simufilam in Alzheimer’s Disease Expected Cassava Sciences, Inc . (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the third quarter ended September 30, 2022 and provided a clinical update on its Phase 3 clinical... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced that it has filed a lawsuit in federal court against certain individuals who executed a “short and distort” campaign against the Company. The 150+ page complaint alleges that the Defendants’ disinformation campaign caused a precipitous decline in Cassava Sciences’ stock price, a multi-billion dollar decline in its market... Read More

Chris Cook, A Skilled Litigator, To Join Management Team as General Counsel New Position Is Expected to Be Critical to Operations and Strategic Initiatives Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced the expansion of its leadership team with the appointment of Christopher Cook as Senior Vice President and General Counsel. This is a newly created... Read More

Alzheimer’s Patients Who Complete Participation in a Phase 3 Study of Simufilam are Eligible to Enroll 52-week Study of Simufilam 100 mg Up to 1,600 Patients Are Expected to Enroll Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of an open-label extension study. This study is designed to provide no-cost access to simufilam, an... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24 th Annual Global Investment Conference, being held in New York. Remi Barbier, President & CEO, will participate in-person at this corporate event. Institutional investors who are registered for this conference may log... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, was recently informed by the Journal of Prevention of Alzheimer's Disease (JPAD) that there is no convincing evidence to support allegations of data manipulation in a 2020 paper on simufilam co-authored by the Company’s personnel and its science collaborators. JPAD communicated the following statement to the Company... Read More

Phase 3 Program - Over 400 Patients Are Now Enrolled in Our Phase 3 Clinical Studies. Open-label Study – Results of an Interim Analysis on the First 100 Patients Who Have Completed at Least 12 Months of Open-label Treatment with Simufilam Follow: Drug Appears Safe and Well Tolerated. Overall ADAS-Cog11 Scores Improved an Average of 1.5 Points (S.D. ± 6.6; P<0.05) 63% of the 100 Patients Showed an Improvement in ADAS-Cog11... Read More

In November 2021, Cassava Sciences previously disclosed that certain government agencies had asked for corporate information and at that time, the media widely reported on these prior disclosures. No government agency has informed Cassava Sciences that it has found any evidence of research misconduct or any other wrong-doing. No government agency has filed any charges against Cassava Sciences. Cassava Sciences, Inc. (Nasdaq:... Read More

$209.7 Million Cash and Cash Equivalents at March 31, 2022 Over 120 Patients Now Enrolled in Phase 3 Program Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’... Read More

Q&A Session at Conference on Wednesday, April 27 th at 1:30PM Eastern Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 27-28, 2022. Remi Barbier, President & CEO, will participate in a Q&A session hosted by B. Riley... Read More

All Stakeholder Are Welcome to Listen by Webcast Event To Be Held Tuesday, April 5 th , 9am ET Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced webcast details for an upcoming, previously announced presentation and fireside chat with Remi Barbier, President & CEO and Eric Schoen, Chief Financial Officer. This event is scheduled to take place on... Read More

CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates Stakeholders Are Invited to Submit Questions via Email Fireside Chat Will Be Open to The Public via Webcast Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier, its President & CEO, will discuss clinical and corporate updates for Q1 2022 in a fireside chat and... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2021 and provided clinical and business updates. “In second half 2021, we initiated two separate Phase 3 clinical studies with our lead drug candidate, simufilam, in patients with Alzheimer’s disease,” said Remi Barbier, President & CEO. “This was a... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that the U.S. Food and Drug Administration ("FDA") denied a Citizen Petition that was filed in August 2021 by an attorney on behalf of short-selling clients. FDA also denied four supplements to the August 2021 Citizen Petition. FDA also denied a September 2021 Citizen Petition, and a supplement, that... Read More

New website (www.Rethink-ALZ.com) is intended to increase visibility and information for potential study participants. Rethink-ALZ.com connects patients with nearest participating clinical site. Phase 3 efficacy studies now in over 25 clinical sites across the country. Cassava Sciences, Inc. , (NASDAQ: SAVA) a biotechnology company, today announced the launch of a new clinical website, called www.Rethink-ALZ.com.... Read More

Editor-in-Chief States: “After Careful Examination of These Original Material, Neuroscience [Journal] Found No Evidence of Manipulation of the Western Blot Data or Other Figures of This Publication.” Clearance Is From A Neutral Party Who Is Expert In The Field Cassava Sciences, Inc. , (Nasdaq: SAVA) a biotechnology company, has been informed by Neuroscience journal there is no evidence to support claims of data manipulation... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, announced today it has initiated a second Phase 3 study of simufilam, the Company’s investigational drug for patients with Alzheimer’s disease. This second Phase 3 study is designed to evaluate the safety and efficacy of simufilam over 78 weeks in approximately 1,000 patients with Alzheimer’s disease across clinical sites in the U.S. and Canada. “Alzheimer’s... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the third quarter ended September 30, 2021. Net loss for the third quarter ended September 30, 2021, was $9.6 million, or $0.24 per share, compared to a net loss of $1.4 million, or $0.06 per share, for the same period in 2020. Net cash used in operations was $22.2 million during... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA) has been informed by the Journal of Neuroscience that there is no evidence of data manipulation in an article it published in July 2012 describing a new approach to treating Alzheimer's disease 1 . The peer-reviewed article was co-authored by scientists and academic collaborators for Cassava Sciences and is foundational to simufilam, the Company’s lead drug candidate for the proposed... Read More

First Phase 3 Study is Initiated to Evaluate Safety and Efficacy of Simufilam Over 52 Weeks in 750 Patients with Alzheimer’s Disease A Second Phase 3 Study, Expected to Begin by Year End, Will Evaluate Simufilam Over 78 Weeks In 1,000 Patients with Alzheimer’s Disease Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today it has initiated an initial Phase 3 efficacy... Read More

Cognition Scores Improved 3.2 Points on ADAS-Cog, Baseline to Month 12 (p<0.001) Two Independent Biostatisticians Analyzed Changes in ADAS-Cog Scores, Baseline to Month 12 No Behavior Disorders on NPI in Over 50% Of Study Subjects at Month 12 Initiation of Pivotal Phase 3 Clinical Program Remains On-track for Q4 2021, with Special Protocol Assessments from FDA Cassava Sciences, Inc. (Nasdaq: SAVA) announced top-line clinical... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that management will present at H.C. Wainwright’s 23 rd Annual Global Investment Conference, a virtual event that takes place September 13-15, 2021. Cassava Sciences’ presentation is a ‘fireside chat’ with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C.... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a public statement regarding recent allegations made against the Company. “Let me be very clear: I think these allegations are false,” said Remi Barbier, President & CEO. “The allegations claim our science is improbable, unexpected and unique to Cassava Sciences, and therefore it’s all an elaborate fraud. By these... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients with Alzheimer’s disease. For this study, Cassava Sciences contracted with Quanterix Corp., a highly regarded, independent laboratory, to perform sample testing on blinded samples. The... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today issued a response to claims that were posted on-line yesterday after market hours. Cassava Sciences believes the claims made in this post regarding scientific integrity are false and misleading. The Company stands behind its science, its scientists and its scientific collaborators, and is responding to ensure the facts are... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for both of its pivotal Phase 3 studies of oral simufilam for the treatment of patients with Alzheimer’s disease. These SPA agreements document that FDA has reviewed and agreed upon the key design... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the second quarter ended June 30, 2021. Net loss for the second quarter ended June 30, 2021, was $5.1 million, or $0.13 per share, compared to a net loss of $1.1 million, or $0.05 per share, for the same period in 2020. Net cash used in operations was $7.4 million during the... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, will release financial results for the period ending June 30, 2021 on Tuesday, August 3, 2021 before the market opens, followed by a conference call. Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will host a conference call to review financial results and to preview the Company’s growth strategy. The... Read More

Simufilam Significantly Improves Cognition in Patients with Alzheimer’s in Interim Analysis of Open-label Study at 9 Months Cognition Improved 3.0 Points on ADAS-Cog at 9 Months ( p<0.001) Cognitive Improvements Track with Biomarker Improvements No Behavior Disorders in Over 50% of Patients No Safety Issues Improvements in Cognition, Biomarkers and Behavior Suggest Highly Encouraging Treatment Effects Oral Presentation at... Read More

SavaDx Detected Significant Changes in Plasma Levels of Altered Filamin A in Patients with Alzheimer’s Disease Before and After Simufilam Treatment Simufilam 100 mg and 50 mg Reduced Plasma Levels of Altered Filamin A in Alzheimer’s Patients 48% (p=0.003) and 44% (p=0.02) Respectively Plasma Results with SavaDx Track Plasma Results with p-Tau181 Plasma Data Provide Evidence of Target Engagement Poster Presentation at AAIC... Read More

On Monday, July 26 th , New Clinical Data for SavaDx to be Shared in a Poster Presentation On Thursday, July 29 th , New Clinical Data for Simufilam to be Featured in a Podium Presentation Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced it will present two new clinical datasets for its product candidates at the 2021 Alzheimer’s Association International... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the selection of Premier Research International as its clinical research organization (CRO) to help conduct the Phase 3 clinical program of simufilam for Alzheimer’s disease. Consistent with previous guidance, Cassava Sciences plans to initiate this Phase 3 program in the second half of 2021. “Having completed over... Read More

Open-label Study Completes Patient Enrollment Cognition Maintenance Study Initiated May 2020, now 30% Enrolled 6-month Biomarker Data to be Presented at AAIC Conference in July 9-month Safety & Cognition Data to be Presented at AAIC Conference Clinical Results with SavaDx to be Presented at AAIC Conference Phase 3 Program Initiation Remains On-track for 2 nd Half 2021 Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference, a virtual event taking place on June 21-23, 2021. Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, will present a corporate overview on Tuesday, June 22 nd at 3:20pm Eastern time.... Read More

Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of Mr. Richard (Rick) Barry to the Company’s Board of Directors, effective June 11, 2021. “We’re very pleased to add Rick Barry as an independent director,” said Remi... Read More

Virtual Panel to be Held on Wednesday, May 26 th , 11:00am Eastern Time Discussion to be Moderated by Jason McCarthy, PhD, Head of Biotechnology Research at Maxim Group Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced it will participate in a Q&A panel discussion focused on innovative treatment approaches for Alzheimer’s disease. Jason McCarthy,... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been awarded a new $2.7 million research grant award from the National Institutes of Health (NIH). This research grant is intended to fund clinical readiness activities in support of Cassava Sciences’ upcoming Phase 3 program with simufilam, its drug candidate for Alzheimer’s disease. "We... Read More

Randomized, Controlled Study is Designed to Evaluate Cognition in Patients Who Continue Versus Discontinue Simufilam Over Six Months Target Enrollment is 100 Study Participants Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of a Cognition Maintenance Study (CMS) to evaluate simufilam in patients with Alzheimer’s disease. Simufilam... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 28-29, 2021. The B. Riley Securities' Neuroscience Conference will cover key topics across neurodegeneration and neuropsychiatry disease areas with leading companies in... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the Sachs 4 th Annual Neuroscience Innovation Forum, a virtual event held on April 28-30, 2021. The National Institute on Aging of the National Institutes of Health (NIH) has invited Cassava Sciences to showcase its scientific program at this event. Lindsay... Read More

9 Month Interim Analysis of Open-label Study to be Presented at a Major Scientific Conference in July 2021 as an Oral Presentation Initiation of Pivotal Phase 3 Program Remains On-track for 2 nd Half 2021 Initiation of Cognition Maintenance Study On-track for June 2021 Cash and cash equivalents were $282.2 million at March 31, 2021 Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2020 and provided business updates. Unaudited cash and cash equivalents were approximately $280 million as of February 2021. “In Q1 2021 we announced that our lead drug candidate, simufilam, improved cognition scores in 50 patients with Alzheimer’s... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, today announced it has entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease. “I am pleased with... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been invited to present at the H.C. Wainwright Global Life Sciences Conference, a virtual event being held Tuesday, March 9 th , and Wednesday, March 10 th , 2021. Management is scheduled to present and will participate in virtual one-on-one meetings with institutional analysts and... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been invited to present at the 10th Annual SVB Leerink Global Healthcare Conference. Remi Barbier, President & CEO, and Eric Schoen, Chief Financial Officer, are scheduled to present on Thursday, February 25 th at 2:20pm Eastern time and will participate in virtual one-on-one meetings with... Read More

Two Upcoming Phase 3 Studies and a Previously Completed Phase 2 Program Support a New Drug Application Filing for Simufilam in Alzheimer’s disease Agreement Reached to Use ADAS-Cog as Co-Primary Efficacy Endpoint Pivotal Phase 3 Program Remains On-track to be Initiated 2 nd Half 2021 Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company developing product candidates for Alzheimer’s disease, today announced the... Read More

Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 4,081,633 shares of its common stock, at a purchase price per share of $49.00, for gross proceeds of approximately $200.0 million. H.C. Wainwright & Co. acted as the exclusive placement agent... Read More